Mon, Sep 22, 2014, 1:26 AM EDT - U.S. Markets open in 8 hrs 4 mins

Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

  • robertvince robertvince Jul 16, 2012 7:45 AM Flag

    Alnylam Pharma reports positive ALN-TTR02 clinical data

    :00AM Alnylam Pharma reports positive ALN-TTR02 clinical data, with robust knockdown of serum transthyretin of up to 94% after single dose (ALNY) 12.52 : Co announces the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis. Results from this study show that administration of ALN-TTR02 leads to robust knockdown of serum TTR protein levels of up to 94%; the overall results were highly significant. Suppression of TTR, the disease-causing protein in ATTR, was found to be rapid, dose dependent, durable, and specific after just a single dose. Co recently reported that it has initiated a Phase II study of ALN-TTR02 in patients with ATTR and has guided that its goal is to start a pivotal trial in 2013.

 
ALNY
77.77-0.41(-0.52%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.